Premium
Co‐Delivery of Docetaxel and p44/42 MAPK siRNA Using PSMA Antibody‐Conjugated BSA‐PEI Layer‐by‐Layer Nanoparticles for Prostate Cancer Target Therapy
Author(s) -
Pang SeeTong,
Lin FengWei,
Chuang ChengKeng,
Yang HungWei
Publication year - 2017
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201600421
Subject(s) - polyethylenimine , chemistry , mapk/erk pathway , docetaxel , bovine serum albumin , glutamate carboxypeptidase ii , small interfering rna , cancer research , antibody , microbiology and biotechnology , biophysics , prostate cancer , pharmacology , kinase , cancer , transfection , medicine , biochemistry , immunology , biology , gene
How to overcome the low accumulation of chemotherapeutic agent in tumor tissue and exhibit multitherapeutics remains an ongoing challenge for cancer treatment. Here, a simple method is demonstrated that used to prepare prostate‐specific membrane antigen antibody (PSMA ab )‐conjugated fluorescent bovine serum albumin (BSA)‐branched polyethylenimine layer‐by‐layer nanoparticles (BSA‐PEI LBL NPs) for co‐delivery of docetaxel (DTX) and p44/42 mitogen‐activated protein kinase (MAPK) small interfering RNA (p44/42 MAPK siRNA) as synergistic and selective inhibition of cancer cell proliferation platform. The results show the levels of α‐tubulin and p44/42 MAPK in CWR22R cells are significantly reduced after treatment with PSMA ab ‐conjugated DTX/BSA‐PEI LBL /siRNA NPs. Consequently, the 50% cellular growth inhibition (IC 50 ) values of the NPs loaded with both DTX and p44/42 MAPK siRNA are ≈2.1‐fold less than those for the NPs only loaded with DTX. The median survival significantly prolongs from 18 d to upward 45 d compared to mice that receive same dose (12 mg kg −1 ) of free DTX. The results suggest this synergistic delivery system may be a promising clinical treatment in prostate cancer.